Clinical trials that target human endogenous retroviruses to treat multiple sclerosis, ALS, and other ailments are underway, but many questions remain about how these sequences may disrupt our biology.
Rashmi Shivni, Drug Discovery News | May 20, 2023 | 10 min read
George Church is at it again, this time using multiplex gene editing to create virus-proof cells, improve organ transplant success, and protect elephants.
Brianna Chrisman and Jordan Eizenga | Sep 1, 2022 | 10+ min read
Thirty years out from the start of the Human Genome Project, researchers have finally finished sequencing the full 3 billion bases of a person’s genetic code. But even a complete reference genome has its shortcomings.
Ryan Layer, The Conversation | May 27, 2022 | 5 min read
Tumors contain thousands of genetic changes, but only a few are actually cancer-causing. A quicker way to identify these driver mutations could lead to more targeted cancer treatments.
The Scientist and Jerome Siegel | Mar 1, 2016 | 10+ min read
Once believed to be unique to birds and mammals, sleep is found across the metazoan kingdom. Some animals, it seems, can’t live without it, though no one knows exactly why.
Shake the family tree of a patient with a movement disorder, and more and more genes are apt to tumble out. Parkinson's disease and many less well-known movement disorders are now considered to be more familial than scientists had previously thought. "When it comes to Parkinson's disease, the important role of genetics as a decisive factor in the appearance and evolution of the disease is gaining more and more ground," says Eduard Tolosa, chairman of the department of neurology at the University
The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.